Antula Acquisition Expands Meda's OTC Portfolio, Marketing Expertise
This article was originally published in The Tan Sheet
Meda's acquisition of fast-growing Swedish OTC firm Antula Healthcare brings on board "proven" marketing expertise to boost existing product sales, a well-established nonprescription drug portfolio and a prolific pipeline for long-term growth.
You may also be interested in...
Meda Pharmaceuticals bolstered its recently established U.S. presence by acquiring three supplement brands from GlaxoSmithKline.
Meda Pharmaceuticals acquires a larger U.S. presence with an eye on OTC growth, including potential switch candidates
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.